Nine drugmakers have agreed to sell select products to state Medicaid programs at the lowest prices paid by other developed nations under the most-favored-nation system, bringing total participants to 26 according to some reports. Verified details confirm the companies and the Medicaid focus, while savings projections of $500-600 billion over a decade remain disputed across sources. The policy applies only to Medicaid and contrasts with broader coverage proposals.